Human Probable cation-transporting ATPase 13A2 (ATP13A2) ELISA Kit

From Assay Genie, this competitive ELISA kit enables quantitative measurement of human Probable cation-transporting ATPase 13A2 (ATP13A2), also referred to as PARK9. The target protein is implicated in neurodegenerative conditions such as Parkinson's disease and Kufor-Rakeb syndrome, where it contributes to intracellular cation homeostasis and the maintenance of neuronal integrity.

Validated for human samples including serum, plasma, saliva, urine, cell culture supernatant, and tissue preparations, the assay offers a detection range of 0.78-50ng/mL and a sensitivity of 0.23ng/mL. Precision is supported by an intra-assay CV of 4.6% and an inter-assay CV of 7.4%. Spike recovery averages 88% (range 82-94%) in serum and 90% (range 84-96%) in plasma. The kit employs a competitive binding immunoassay, with absorbance read at 450 nm.

Designed for research use only, the kit is classified within the Neurosciences research area and recognises both natural and recombinant human Cation-transporting ATPase 13A2. Reagents are stored at -20°C, with the substrate kept at 4°C.